Legal entity
Every one of those 1 sits in a single category, regulation. National Centre for Pharmacoeconomics (NCPE) is most often covered alongside Biogen, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 5.5.
Last mentioned: Aug 3, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, regulation. National Centre for Pharmacoeconomics (NCPE) is most often covered alongside Biogen, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 5.5. They are less corroborated than the beat average, carrying 2 original sources each against 2.3 for the same window. We currently track 1 Legal story that mention National Centre for Pharmacoeconomics (NCPE), all published on August 3, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering National Centre for Pharmacoeconomics (NCPE). Shared-story counts are live from our verified record — not editorial picks.
High Court grants permission for judicial review
Judge Cian Ferriter allows Emily Felix's challenge against the HSE and Minister for Health to proceed, citing arguable grounds regarding the delay.
NCPE pharmacoeconomic evaluation completed
The National Centre for Pharmacoeconomics delivers its assessment of Skyclarys' cost-effectiveness to the HSE.
HSE reimbursement application filed
Biogen submits a formal pricing and reimbursement application to the HSE to add Skyclarys to the public drug list.
European market authorisation
The European Commission grants centralised marketing authorisation for Biogen's Skyclarys (omaveloxolone) for patients over 16.
Diagnosis with Friedreich's ataxia
Emily Felix, then 12 years old, is diagnosed with the rare, progressive neuromuscular disease.
Emily Felix, 28, launches judicial review against the HSE for failing to decide on funding for Biogen's Friedreich's ataxia drug for nearly two years, despite EMA approval and availability across a dozen EU nations.
National Centre for Pharmacoeconomics (NCPE) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
